Skip to main content
Clinical Trials/NCT01393886
NCT01393886WithdrawnPhase 2

A Prospective, Open-label Study to Evaluate the Safety and Efficacy of Laparoscopic Greater Curvature Plication (LGCP) in the Treatment of Obese Patients

NYU Langone Health1 site in 1 countryStarted: June 2013Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Withdrawn
Locations
1
Primary Endpoint
Weight Loss

Study Overview

Brief Summary

The aim of this study is to find out the safety and efficacy of Laparoscopic Greater Curvature Plication (LGCP) procedure. This study procedure is an alternative restrictive weight loss surgery that has the potential to reduce the complications associated with gastric banding and sleeve gastrectomy by creating a small sized stomach without the use of an implant and without cutting stomach.

Detailed Description

STUDY OBJECTIVES: To demonstrate the safety and efficacy of Laparoscopic Greater Curvature Plication (LGCP)

DESIGN: Prospective, open-label, and single center

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subject is at least 18 years of age at the time of enrollment into the study;
  • Have a BMI of at least 30;
  • Subject is willing to give consent and comply with protocol evaluation and treatment schedules;
  • Subject agrees to refrain from any type of weight-loss drug (prescription or OCT) or elective procedure that affect body weight for the duration of the trial; and
  • HbA1C<11%

Exclusion Criteria

  • History of previous malabsorptive bariatric procedures;
  • Women of childbearing potential who are pregnant or lactating at the time of screening or at the time of surgery;
  • Any condition which precludes compliance with the study;
  • History or presence of pre-existing autoimmune connective tissue disease; and
  • Use of prescription or over the counter weight reduction medications or supplements within 30 days of the screening visit or the duration of study participation.
  • This study is a local study (NY, within 50 miles). This study is not a sponsored trial. Therefore, the procedure is not free.

Outcomes

Primary Outcomes

Weight Loss

Time Frame: 12 months

The primary effectiveness endpoint is % of subjects who attain clinically successful weight loss at one year post LGCP.

Secondary Outcomes

  • Morbidity rates(12 months)
  • Mortality rates(12 month)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Heekoung A Youn

Research coordinator

NYU Langone Health

Study Sites (1)

Loading locations...

Similar Trials